C4 Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

CCCC$3.15+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 15. Exhibits, Financial Statement Schedules

Financial Statements

For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.

Financial Statement Schedules

Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.

Exhibits

ExhibitNumber	Description of Exhibit	Form	FileNumber	Date ofFiling	ExhibitNumber	FiledHerewith
3.1	Fifth Amended and Restated Certificate of Incorporation of the Registrant	8-K	001–39567	10/06/2020	3.3
3.2	Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Registrant	DEF14A	001–39567	04/28/2023	A
3.3	Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of the Registrant	8-K	001–39567	06/18/2025	3.1
3.4	Form of Second Amended and Restated Bylaws of the Registrant	S-1	333–248719	09/10/2020	3.5
4.1	Form of Specimen Common Stock Certificate	S-1/A	333–248719	09/28/2020	4.3
4.2	Form of Pre-Funded Warrant	8-K	001–39567	10/16/2025	4.1
4.3	Form of Class A Warrant	8-K	001–39567	10/16/2025	4.2
4.4	Form of Class B Warrant	8-K	001–39567	10/16/2025	4.3
4.5	Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended					X
10.1#	2015 Stock Option and Grant Plan, as amended and forms of award agreements thereunder	S-1	333–248719	09/10/2020	10.1
10.2#	2020 Stock Option and Incentive Plan and forms of award agreements thereunder	10-K	001-39567	02/23/2023	10.2
10.3#	Form of Non-Qualified Stock Option Agreement for Inducement Grants	10-K	001-39567	02/22/2024	10.19
10.4#	2020 Employee Stock Purchase Plan	S-1/A	333–248719	09/28/2020	10.3
10.5#	Senior Executive Cash Incentive Bonus Plan	S-1	333–248719	09/10/2020	10.4
10.6#	Form of Director Indemnification Agreement	S-1	333–248719	09/10/2020	10.5
10.7#	Form of Officer Indemnification Agreement	S-1	333–248719	09/10/2020	10.6
10.8#	Form of Executive Employment Agreement	S-1	333–248719	09/10/2020	10.7
10.9#	Employment Agreement between the Registrant and Andrew Hirsch, dated September 6, 2020	S-1	333–248719	09/10/2020	10.8
10.10†	Collaborative Research and License Agreement between the Registrant and Biogen MA, Inc., dated December 28, 2018	S-1	333–248719	09/10/2020	10.10

ExhibitNumber	Description of Exhibit	Form	FileNumber	Date ofFiling	ExhibitNumber	FiledHerewith
10.11†	Amendment No. 1 to Collaborative Research and License Agreement between the Registrant and Biogen MA, Inc., dated February 25, 2020	10-K	001-39567	03/11/2021	10.11
10.12†	Amended and Restated License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated December 20, 2018	S-1	333–248719	09/10/2020	10.11
10.13†	First Amendment to the Amended and Restated License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated November 12, 2020	10-K	001-39567	03/11/2021	10.13
10.14	Lease by 480 Arsenal Group LLC to the Registrant, dated July 5, 2017, as amended	S-1	333–248719	09/10/2020	10.14
10.15	Third Amendment to Lease, dated November 24, 2021, by and between C4 Therapeutics, Inc. and Columbia Massachusetts Arsenal Office Properties, LLC	8-K	001-39567	11/30/2021	10.1
10.16†	License and Collaboration Agreement, dated May 29, 2023, by and between C4 Therapeutics, Inc. and Betta Pharmaceuticals Co., Ltd.	8-K	001-39567	05/30/2023	10.1
10.17†	Research Collaboration and License Agreement dated March 1, 2024, by and between C4 Therapeutics, Inc., and Merck KGaA, Darmstadt, Germany	10-Q	001-39567	05/08/2024	10.1
10.18#	Form of Performance-Accelerated Restricted Stock Unit Award Agreement					X
19.1	Company Policy on Insider Trading and Disclosure, Special Trading Procedures for Insiders, and Rule 10b5-1 Trading Plan Policy	10-K	001-39567	02/27/2025	19.0
21.1	Subsidiaries of the Registrant					X
23.1	Consent of KPMG LLP, Independent Registered Public Accounting Firm					X
31.1	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					X
31.2	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002					X
32.1*	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002					X
97	Executive Compensation Recovery Policy	10-K	001-39567	02/22/2024	97

ExhibitNumber	Description of Exhibit	Form	FileNumber	Date ofFiling	ExhibitNumber	FiledHerewith
101.INS	Inline XBRL Instance Document					X
101.SCH	Inline XBRL Taxonomy Extension Schema Document					X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document					X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document					X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document					X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document					X
104	Cover Page Interactive Data File (formatted as Inline XBRL document and contained in Exhibit 101)

#	Indicates a management contract or any compensatory plan, contract or arrangement.
†	Portions of this exhibit (indicated by asterisks) will be omitted in accordance with the rules of the Securities and Exchange Commission.
*	Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act, or the Exchange Act, except as otherwise stated in such filing.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.